Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5563050 | 0.93 | RXFP1 (0.45) | RXFP1DRD2DRD3KMT2ANPC1 | |
| SCHEMBL5564192 | 0.92 | RXFP1 (0.46) | RXFP1DRD2DRD3KMT2ANPC1 | |
| SCHEMBL5564059 | 0.85 | NPC1 (0.47) | RXFP1DRD2DRD3KMT2ANPC1 | |
| SCHEMBL5565724 | 0.83 | NPC1 (0.44) | RXFP1DRD2DRD3KMT2ANPC1 | |
| SCHEMBL5564847 | 0.83 | RXFP1 (0.44) | RXFP1NPC1CNR2KDM4EALDH1A1 | |
| SCHEMBL5564958 | 0.82 | RXFP1 (0.45) | RXFP1DRD2DRD3NPC1POLB | |
| SCHEMBL5563555 | 0.81 | RAB9A (0.44) | RXFP1KMT2ANPC1POLBMEN1 | |
| SCHEMBL5566157 | 0.81 | RAB9A (0.41) | KMT2ANPC1POLBMEN1CNR2 | |
| SCHEMBL5564644 | 0.80 | NPC1 (0.40) | NPC1CNR2KDM4EALDH1A1 | |
| SCHEMBL6445501 | 0.80 | HSP90AA1 (0.41) | RXFP1DRD2DRD3KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208491-B2 | N-monoacylated o-phenylenediamines | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20040157841-A1 | inhibition of histone deacetylase; for inhibiting cell proliferation; cancer therapy | HOFFMANN-LA ROCHE INC. | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157841-A1 | inhibition of histone deacetylase; for inhibiting cell proliferation; cancer therapy | HDAC1, HDAC11, HDAC7 | RXFP1 2974/4885DRD2 2819/4885DRD3 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.